Target intelligence / Profile preview

Dedicator of cytokinesis protein 3 (DOCK3)

Target: DOCK3
Molecular classification: Guanine nucleotide exchange factor (GEF), DOCK-B subfamily, Cytoskeletal regulatory protein

Overview

Dedicator of cytokinesis protein 3 (DOCK3) is a large cytoplasmic protein (~180 kDa) predominantly expressed in the central nervous system, especially in neurons of the cerebral cortex and hippocampus[3]. As a guanine nucleotide exchange factor, DOCK3 activates the small G-protein Rac1, leading to reorganization of the cytoskeleton and the promotion of neurite outgrowth, cell adhesion, migration, fusion, and viability[1][2][3][6]. It interacts with presenilin and is implicated in Alzheimer’s disease, and its deficiency causes intellectual disability, muscle hypotonia, and developmental delays[1][2][5][6]. DOCK3 forms protein complexes with Elmo1 and is being explored as a therapeutic target for neuroprotection and axon regeneration in preclinical models[4][6].

Other names: DOCK3MOCAPBPModifier of cell adhesionPresenilin-binding proteinKIAA0299NEDIDHADock3

Mechanism of action

Stimulation of GEF activity to activate Rac1 and promote actin dynamics; Enhancement of DOCK3-Elmo1 interaction to facilitate axon regeneration and neuroprotection

Biological functions

Signal transduction via small G-proteins (Rac1)Cell adhesionCytoskeleton reorganizationAxonal outgrowth and neurite extensionMuscle fusion and differentiation

Disease associations

Neurodevelopmental disorder with impaired intellectual development, hypotonia, and ataxiaNon-specific syndromic intellectual disabilityAttention deficit hyperactivity disorder (ADHD)-like phenotypeAlzheimer’s disease (through interaction with presenilin)Muscular dystrophies (e.g., Duchenne Muscular Dystrophy)

Safety considerations

Knockout or deficiency of DOCK3 leads to severe neurodevelopmental disability, hypotonia, and ataxic gait, indicating that inhibition or loss of DOCK3 function could produce significant neurological and musculoskeletal side effects.

Interacting drugs

Currently, there are no approved drugs directly targeting DOCK3. However, low-molecular-weight compounds have been identified that enhance DOCK3-Elmo1 interaction and stimulate neurite outgrowth and neuroprotection in preclinical models.

Biomarkers

DOCK3 expression level in muscle may serve as a potential biomarker for Duchenne Muscular Dystrophy severity.

Beyond the preview

Go deeper on Dedicator of cytokinesis protein 3 (DOCK3).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dedicator of cytokinesis protein 3 (DOCK3).

Explore the full profile